MED-EL announces FDA approval for the new rechargeable DaCapo
battery and charging system
Durham, NC – (May 19, 2008) – MED-EL has received approval by the US Food and Drug Administration for its new rechargeable DaCapo battery and charging system.
The DaCapo system was developed for the MED-EL OPUS 1, OPUS 2 and TEMPO+ speech processors. MED-EL speech processors continue to be the lightest and slimmest available. The DaCapo system additionally reduces the weight by another 20% without limiting performance.
DaCapo is an environmentally friendly and very convenient alternative to the existing battery options. The system is shipped with a charging unit and three PowerPacks, rechargeable batteries each lasting for 10-12 hours. It is compatible with most FM systems and other external hearing devices (e.g. Bluetooth® with OPUS 2). DaCapo is available in all six frame colors for a perfect match with existing MED-EL speech processor colors.
About MED-EL Corporation
Since its founders developed one of the world’s first cochlear implants in 1975, MED-EL has set new standards in hearing implant technologies, developing and manufacturing technologically advanced hearing solutions for people with varying degrees of hearing loss. MED-EL hearing implant systems, currently used in 70 countries, combines the latest scientific advances, engineering and manufacturing techniques for performance, safety and reliability. For more information, visit www.medel.com or call 888-MED-EL-CI (633-3524).
MED-EL announces FDA approval for the new rechargeable DaCapo 
